Salem Kelley, Kumar Manoj, Powers Ginny L, Jeffery Justin J, Yan Yongjun, Mahajan Aparna M, Fowler Amy M
From the Department of Radiology (K.S., M.K., G.L.P., Y.Y., A.M.F.), Carbone Cancer Center (J.J.J., A.M.F.), Department of Medical Physics (Y.Y., A.M.F.), and Department of Pathology and Laboratory Medicine (A.M.M.), University of Wisconsin School of Medicine and Public Health, 600 Highland Ave, Madison, WI 53792.
Radiology. 2018 Mar;286(3):856-864. doi: 10.1148/radiol.2017162956. Epub 2017 Sep 25.
Purpose To determine the binding specificity of F-16α-17β-fluoroestradiol (FES) in estrogen receptor (ER) α-positive breast cancer cells and tumor xenografts. Materials and Methods Protocols were approved by the office of biologic safety and institutional animal care and use committee. By using ER-negative MDA-MB-231 breast cancer cells, clonal lines were created that expressed either wild-type (WT; 231 WT ER) or G521R mutant ERα (231 G521R ER), which is defective in estradiol binding. ERα protein levels, subcellular localization, and transcriptional function were confirmed. FES binding was measured by using an in vitro cell uptake assay. In vivo FES uptake was measured in tumor xenografts by using small-animal positron emission tomographic/computed tomographic imaging of 24 mice (17 WT ER tumors, nine mutant G521R ER tumors, eight MDA-MB-231 tumors, and four MCF-7 ER-positive tumors). Statistical significance was determined by using Mann-Whitney (Wilcoxon rank sum) test. Results ERα transcriptional function was abolished in the mutated 231 G521R ER cells despite appropriate receptor protein expression and nuclear localization. In vitro FES binding in the 231 G521R ER cells was reduced to that observed in the parental cells. Similarly, there was no significant FES uptake in the 231 G521R ER xenografts (percent injected dose [ID] per gram, 0.49 ± 0.042), which was similar to the negative control MDA-MB-231 xenografts (percent ID per gram, 0.42 ± 0.051; P = .20) and nonspecific muscle uptake (percent ID per gram, 0.41 ± 0.0095; P = .06). Conclusion This study showed that FES retention in ER-positive breast cancer is strictly dependent on an intact receptor ligand-binding pocket and that FES binds to ERα with high specificity. These results support the utility of FES imaging for assessing tumor heterogeneity by localizing immunohistochemically ER-positive metastases that lack receptor-binding functionality. RSNA, 2017 Online supplemental material is available for this article.
目的 确定F-16α-17β-氟雌二醇(FES)在雌激素受体(ER)α阳性乳腺癌细胞和肿瘤异种移植物中的结合特异性。材料与方法 实验方案经生物安全办公室和机构动物护理与使用委员会批准。利用ER阴性的MDA-MB-231乳腺癌细胞,创建了表达野生型(WT;231 WT ER)或G521R突变型ERα(231 G521R ER)的克隆细胞系,后者在雌二醇结合方面存在缺陷。对ERα蛋白水平、亚细胞定位和转录功能进行了确认。通过体外细胞摄取试验测量FES结合情况。通过对24只小鼠(17个WT ER肿瘤、9个突变型G521R ER肿瘤、8个MDA-MB-231肿瘤和4个MCF-7 ER阳性肿瘤)进行小动物正电子发射断层扫描/计算机断层扫描成像,测量肿瘤异种移植物中FES的摄取情况。采用Mann-Whitney(Wilcoxon秩和)检验确定统计学意义。结果 尽管受体蛋白表达和核定位正常,但在突变的231 G521R ER细胞中,ERα转录功能被消除。231 G521R ER细胞中的体外FES结合减少至亲本细胞中的水平。同样,231 G521R ER异种移植物中没有明显的FES摄取(每克注射剂量百分比[ID],0.49±0.042),这与阴性对照MDA-MB-231异种移植物(每克ID百分比,0.42±0.051;P = 0.20)和非特异性肌肉摄取(每克ID百分比,0.41±0.0095;P = 0.06)相似。结论 本研究表明,FES在ER阳性乳腺癌中的保留严格依赖于完整的受体配体结合口袋,且FES与ERα具有高特异性结合。这些结果支持FES成像在通过定位缺乏受体结合功能的免疫组化ER阳性转移灶来评估肿瘤异质性方面的实用性。RSNA,2017 本文提供在线补充材料。